Rituximab -- sold as the brand name Rituxan -- belongs to a group of cancer drugs classified as monoclonal antibodies, and is used to treat many types of non-Hodgkin's lymphoma. Monoclonal antibodies are utilized to try and destroy some types of cancer cells while causing minimal damage to normal cells. In addition, when rituximab is used along with methotrexate, it can reduce signs and symptoms and slow the progression of structural damage of rheumatoid arthritis in a specific category of adult patients.
- Non-Hodgkin's lymphomas can occur at any age and are five times more common than any other type of lymphoma.
- The cause of rheumatoid arthritis is unknown.
- Rituximab is administered via IV infusion.
- Serious, sometimes fatal side effects can be experienced.